Role of the lymphatic system in the pathogenesis of Crohn's disease

Current Opinion in Gastroenterology

Volumn 27, Issue 4, 2011, Pages 335-341

  Von Der Weid, Pierre Yves ^a   Rehal, Sonia ^a   Ferraz, José G P ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Crohn's disease; dendritic cell trafficking; fat wrapping; inflammation; lymph drainage; lymph node; lymphangiogenesis; lymphangitis; lymphatic pumping; lymphatic vessel

Indexed keywords

SCAVENGER RECEPTOR;

ANIMAL MODEL; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CELL MIGRATION; CELL MOTION; CELL PROLIFERATION; CROHN DISEASE; DISEASE ASSOCIATION; ENTERITIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; LIPID STORAGE; LIPID TRANSPORT; LYMPH VESSEL; LYMPH VESSEL ENDOTHELIUM; LYMPHADENOPATHY; LYMPHANGIOGENESIS; LYMPHANGITIS; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; NONHUMAN; PATHOGENESIS; PHENOTYPE; REVIEW;

CROHN DISEASE; HUMANS; LYMPHANGIOGENESIS; LYMPHANGITIS; LYMPHATIC SYSTEM;

EID: 79958817911     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283476e8f     Document Type: Review

References (74)

1. Kirsner JB. Observations on the etiology and pathogenesis of inflammatory bowel disease. In: Bockus H, editor. Gastroenterology. Philadelphia: Saunders; 1976. pp. 521-539.
2. Kovi J, Duong HD, Hoang CT. Ultrastructure of intestinal lymphatics in Crohn's disease. Am J Clin Pathol 1981; 76:385-394. (Pubitemid 11011284)
3. Robb-Smith AH. A bird's-eye view of Crohn's disease. Proc R Soc Med 1971; 64:157-161.
4. Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis, a pathological and clinical entity. J Am Med Ass 1932; 99:1323-1328.
5. Van Kruiningen HJ, Colombel JF. The forgotten role of lymphangitis in Crohn's disease. Gut 2008; 57:1-4.
6. Heatley RV, Bolton PM, Hughes LE, Owen EW. Mesenteric lymphatic obstruction in Crohn's disease. Digestion 1980; 20:307-313. (Pubitemid 10082955)
7. Bockus H. In: Bockus H, editor. Gastroenterology. Philadelphia: Saunders; 1946. pp. 158-196.
8. Tonelli P. New developments in Crohn's disease: solution of doctrinal mysteries and reinstatement as a surgically treatable disease. 1: The process is not a form of enteritis but lymphedema contaminated by intestinal contents. Chir Ital 2000; 52:109-121.
9. Wu TF, Carati CJ, Macnaughton WK, von der Weid PY. Contractile activity of lymphatic vessels is altered in the TNBS model of guinea pig ileitis. Am J Physiol Gastrointest Liver Physiol 2006; 291:G566-G574. (Pubitemid 44511674)
10. Kalima TV. Experimental lymphatic obstruction in the ileum. Ann Chir Gynaecol Fenn 1970; 59:187-201.
11. Kalima TV, Saloniemi H, Rahko T. Experimental regional enteritis in pigs. Scand J Gastroenterol 1976; 11:353-362.
12. Reichert FL, Mathes ME. Experimental lymphedema of the intestinal tract and its relation to regional cicatrizing enteritis. Ann Surg 1936; 104:610-616.
13. Geleff S, Schoppmann SF, Oberhuber G. Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease. Virchows Arch 2003; 442:231-237. (Pubitemid 36399216)
14. Fogt F, Pascha TL, Zhang PJ, et al. Proliferation of D2-40-expressing intestinal lymphatic vessels in the lamina propria in inflammatory bowel disease. Int J Mol Med 2004; 13:211-214.
15. Kaiserling E, Krober S, Geleff S. Lymphatic vessels in the colonic mucosa in ulcerative colitis. Lymphology 2003; 36:52-61. (Pubitemid 36900181)
16. Pedica F, Ligorio C, Tonelli P, et al. Lymphangiogenesis in Crohn's disease: an immunohistochemical study using monoclonal antibody D2-40. Virchows Arch 2008; 452:57-63.
17. Thaunat O, Kerjaschki D, Nicoletti A. Is defective lymphatic drainage a trigger for lymphoid neogenesis? Trends Immunol 2006; 27:441-445.
18. Karkkainen MJ, Saaristo A, Jussila L, et al. A model for gene therapy of human hereditary lymphedema. Proc Natl Acad Sci U S A 2001; 98:12677-12682. (Pubitemid 33020005)
19. Karlsen TV, Karkkainen MJ, Alitalo K, Wiig H. Transcapillary fluid balance consequences of missing initial lymphatics studied in a mouse model of primary lymphoedema. J Physiol 2006; 574 (Pt 2):583-596.
20. Chaitanya GV, Franks SE, Cromer W, et al. Differential cytokine responses in human and mouse lymphatic endothelial cells to cytokines in vitro. Lymphat Res Biol 2010; 8:155-164. This paper shows a role for inflammatory cytokines in lymphatic endothelial cell growth and permeability that may increase tissue edema. The authors suggest that cytokines blockade may help limiting inflammation.
21. Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006; 6:205-217. (Pubitemid 43290990)
22. Kratz A, Campos-Neto A, Hanson MS, Ruddle NH. Chronic inflammation caused by lymphotoxin is lymphoid neogenesis. J Exp Med 1996; 183:1461-1472. (Pubitemid 26134289)
23. Sura R, Colombel JF, Van Kruiningen HJ. Lymphatics, tertiary lymphoid organs and the granulomas of Crohn's disease: an immunohistochemical study. Aliment Pharmacol Ther 2011; 33:930-939. This study elegantly confirms the association between inflammation, granulomas, tertiary lymphoid follicles, and the lymphatic vasculature in Crohn's disease and the occurrence of lymphangiectasia and lymphocytic perilymphangitis in all patients.
24. Behr MA. The path to Crohn's disease: is mucosal pathology a secondary event? Inflamm Bowel Dis 2010; 16:896-902. This review proposes an 'inside-out' model for Crohn's disease, in which mucosal damage would only be secondary to innocuous mucosal translocation of bacteria infecting lymph nodes and lymphatics and inducing lymphadenitis and fibrotic lymphangiectasia.
25. Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25:665-672. (Pubitemid 14122134)
26. Gourtsoyiannis N, Papanikolaou N, Grammatikakis J, et al. Assessment of Crohn's disease activity in the small bowel with MR and conventional enteroclysis: preliminary results. Eur Radiol 2004; 14:1017-1024. (Pubitemid 38787247)
27. Alexander JS, Chaitanya GV, Grisham MB, Boktor M. Emerging roles of lymphatics in inflammatory bowel disease. Ann N Y Acad Sci 2010; 1207 (Suppl 1):E75-E85. In this review, the authors highlight the importance of lymphatics and lymphangiogenesis in IBDs.
28. Sawa Y, Ueki T, Hata M, et al. LPS-induced IL-6, IL-8, VCAM-1, and ICAM-1 expression in human lymphatic endothelium. J Histochem Cytochem 2008; 56:97-109. (Pubitemid 351170963)
29. Olinde J, Tatum A, Wells SR, et al. Gut sterilization reduces severity of inflammation, disease activity, leukocyte infiltration and angiogenesis in the mouse DSS colitis model [abstract]. CSCR & MWAFMR 2010.
30. von der Weid P-Y, Zawieja DC. Lymphatic smooth muscle: the motor unit of lymph drainage. Int J Biochem Cell Biol 2004; 36:1147-1153. (Pubitemid 38515655)
31. von der Weid PY, Rainey KJ. Review article: lymphatic system and associated adipose tissue in the development of inflammatory bowel disease. Aliment Pharmacol Ther 2010; 32:697-711. This review provides an in-depth assessment of the role of the lymphatic system and adipose tissue in IBDs.
32. Miteva DO, Rutkowski JM, Dixon JB, et al. Transmural flow modulates cell and fluid transport functions of lymphatic endothelium. Circ Res 2010; 106:920-931. This paper provides evidence that transmural fluid flow modulates expression of adhesion molecules and chemokines by the lymphatic endothelium that may affect fluid and cell entry in and transport via lymphatics.
33. Pflicke H, Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J Exp Med 2009; 206:2925-2935.
34. Lammermann T, Bader BL, Monkley SJ, et al. Rapid leukocyte migration by integrin-independent flowing and squeezing. Nature 2008; 453:51-55. (Pubitemid 351630331)
35. Johnson LA, Clasper S, Holt AP, et al. An inflammation-induced mechanism for leukocyte transmigration across lymphatic vessel endothelium. J Exp Med 2006; 203:2763-2777. (Pubitemid 44833351)
36. Johnson LA, Jackson DG. Inflammation-induced secretion of CCL21 in lymphatic endothelium is a key regulator of integrin-mediated dendritic cell transmigration. Int Immunol 2010; 22:839-849. This paper demonstrates that stimulated dendritic cells use a CCL21-dependent mechanism to transmigrate across resting lymphatic endothelium, but inflammation may favor an integrin-dependent mechanism.
37. Kriehuber E, Breiteneder-Geleff S, Groeger M, et al. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J Exp Med 2001; 194:797-808. (Pubitemid 32983015)
38. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002; 21:1505-1513. (Pubitemid 34614607)
39. Gunn MD, Kyuwa S, Tam C, et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999; 189:451-460. (Pubitemid 29187367)
40. Gunn MD, Tangemann K, Tam C, et al. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive T lymphocytes. Proc Natl Acad Sci U S A 1998; 95:258-263. (Pubitemid 28103941)
41. Fagarasan S, Shinkura R, Kamata T, et al. Alymphoplasia (aly)-type nuclear factor kappaB-inducing kinase (NIK) causes defects in secondary lymphoid tissue chemokine receptor signaling and homing of peritoneal cells to the gut-associated lymphatic tissue system. J Exp Med 2000; 191:1477-1486. (Pubitemid 30257345)
42. Mancardi S, Vecile E, Dusetti N, et al. Evidence of CXC, CC and C chemokine production by lymphatic endothelial cells. Immunology 2003; 108:523-530.
43. Vicari AP, Vanbervliet B, Massacrier C, et al. In vivo manipulation of dendritic cell migration and activation to elicit antitumour immunity. Novartis Found Symp 2004; 256:241-254; discussion 54-69.
44. Saeki H, Moore AM, Brown MJ, Hwang ST. Cutting edge: secondary lymphoid-tissue chemokine (SLC) and CC chemokine receptor 7 (CCR7) participate in the emigration pathway of mature dendritic cells from the skin to regional lymph nodes. J Immunol 1999; 162:2472-2475. (Pubitemid 29309263)
45. Middel P, Raddatz D, Gunawan B, et al. Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. Gut 2006; 55:220-227. (Pubitemid 43117282)
46. Taquet N, Dumont S, Vonesch JL, et al. Differential between protein and mRNA expression of CCR7 and SSTR5 receptors in Crohn's disease patients. Mediators Inflamm 2009; 2009:285812.
47. Karikoski M, Irjala H, Maksimow M, et al. Clever-1/Stabilin-1 regulates lymphocyte migration within lymphatics and leukocyte entrance to sites of inflammation. Eur J Immunol 2009; 39:3477-3487.
48. Podgrabinska S, Kamalu O, Mayer L, et al. Inflamed lymphatic endothelium suppresses dendritic cell maturation and function via Mac-1/ICAM-1-dependent mechanism. J Immunol 2009; 183:1767-1779.
49. Abdelbaqi M, Chidlow JH, Matthews KM, et al. Regulation of dextran sodium sulfate induced colitis by leukocyte beta 2 integrins. Lab Invest 2006; 86:380-390.
50. Ghosh S, Panaccione R. Antiadhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol 2010; 3:239-258. This review summarizes and discusses the role of adhesion molecules in IBDs and their potential therapeutic use.
51. Jurisic G, Sundberg JP, Bleich A, et al. Quantitative lymphatic vessel trait analysis suggests Vcam1 as candidate modifier gene of inflammatory bowel disease. Genes Immun 2010; 11:219-231. In this paper, the authors identify VCAM1, an adhesion molecule upregulated by the lymphatic endothelium during inflammation, as a modifier gene for IBDs.
52. Bamias G, Kaltsa G, Siakavellas SI, et al. High intestinal and systemic levels of decoy receptor 3 (DcR3) and its ligand TL1A in active ulcerative colitis. Clin Immunol 2010; 137:242-249.
53. Funke B, Autschbach F, Kim S, et al. Functional characterisation of decoy receptor 3 in Crohn's disease. Gut 2009; 58:483-491.
54. Vetrano S, Borroni EM, Sarukhan A, et al. The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut 2010; 59:197-206. This paper demonstrates the critical role that the decoy receptor D6 on lymphatic vessels plays in the control of intestinal inflammation and the development of inflammation- associated colon cancer.
55. Collins CB, McNamee EN, Wermers JD, et al. Chemokine decoy receptor D6 in inflammatory bowel disease (IBD) and IBD-associated colon cancer. Gut 2010; 59:151-152.
56. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, et al. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007; 56:577-583.
57. Sheehan AL, Warren BF, Gear MW, Shepherd NA. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992; 79:955-958.
58. Borley NR, Mortensen NJ, Jewell DP, Warren BF. The relationship between inflammatory and serosal connective tissue changes in ileal Crohn's disease: evidence for a possible causative link. J Pathol 2000; 190:196-202. (Pubitemid 30082494)
59. Ryan TJ. Lymphatics and adipose tissue. Clin Dermatol 1995; 13:493-498. (Pubitemid 26073919)
60. Dixon JB. Lymphatic lipid transport: sewer or subway? Trends Endocrinol Metab 2010; 21:480-487. This review discusses in light of recent findings the relationship between lipid biology and the lymphatic system.
61. Harvey NL, Srinivasan RS, Dillard ME, et al. Lymphatic vascular defects promoted by Prox1 haploinsufficiency cause adult-onset obesity. Nat Genet 2005; 37:1072-1081. (Pubitemid 41486659)
62. Pond CM. Long-term changes in adipose tissue in human disease. Proc Nutr Soc 2001; 60:365-374. (Pubitemid 32772452)
63. Westcott E, Windsor A, Mattacks C, et al. Fatty acid compositions of lipids in mesenteric adipose tissue and lymphoid cells in patients with and without Crohn's disease and their therapeutic implications. Inflamm Bowel Dis 2005; 11:820-827. (Pubitemid 41368270)
64. Westcott ED, Mattacks CA, Windsor AC, et al. Perinodal adipose tissue and fatty acid composition of lymphoid tissues in patients with and without Crohn's disease and their implications for the etiology and treatment of CD. Ann N Y Acad Sci 2006; 1072:395-400. (Pubitemid 44448473)
65. Plaku KJ. The effect of lymphatic vessel impairment on small bowel physiology and of mesenteric mast cell degranulation upon lymphatic vessel contractility. Calgary: University of Calgary; 2007.
66. Piller NB. Lymphoedema, macrophages and benzopyrones. Lymphology 1980; 13:109-119. (Pubitemid 10003829)
67. Piller NB. Macrophage and tissue changes in the developmental phases of secondary lymphoedema and during conservative therapy with benzopyrone. Arch Histol Cytol 1990; 53 (Suppl):209-218.
68. Rockson SG. Lymphedema. Am J Med 2001; 110:288-295.
69. Shin WS, Szuba A, Rockson SG. Animal models for the study of lymphatic insufficiency. Lymphat Res Biol 2003; 1:159-169.
70. Tabibiazar R, Cheung L, Han J, et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med 2006; 3:e254.
71. Rutkowski JM, Markhus CE, Gyenge CC, et al. Dermal collagen and lipid deposition correlate with tissue swelling and hydraulic conductivity in murine primary lymphedema. Am J Pathol 2010; 176:1122-1129. This paper shows the critical role that fat accumulation plays in tissue swelling and interstitial fluid movement in lymphedema.
72. Desreumaux P, Ernst O, Geboes K, et al. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999; 117:73-81. (Pubitemid 29297622)
73. Lim HY, Rutkowski JM, Helft J, et al. Hypercholesterolemic mice exhibit lymphatic vessel dysfunction and degeneration. Am J Pathol 2009; 175: 1328-1337.
74. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006; 6:244-251. (Pubitemid 43290993)